Effect of lipophilicity on drug distribution and elimination: Influence of obesity
British Journal of Clinical Pharmacology2021Vol. 87(8), pp. 3197–3205
Citations Over TimeTop 10% of 2021 papers
Christopher D. Bruno, Jerold S. Harmatz, Su Duan, Qingchen Zhang, Christina R. Chow, David J. Greenblatt
Abstract
Lipophilicity is a principal correlate of in vivo Vd , as well as the increased Vd of drugs in obese patients. The consequent prolongation of half-life in obesity has clinical safety implications in terms of delayed drug accumulation and washout during and after chronic dosage. The magnitude and importance of this effect for a given drug depends on the degree of obesity, as well as the lipid-solubility of the specific drug.
Related Papers
- → Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution(2003)361 cited
- → Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination(2010)316 cited
- → Modelling of pH dependent n-octanol/water partition coefficients of ionizable pharmaceuticals(2011)48 cited
- → Development and Validation of Liquid Chromatography-Based Methods to Assess the Lipophilicity of Cytotoxic Platinum(IV) Complexes(2018)36 cited
- → Lipophilicity of BODIPY fluorophores and their distribution in 1-octanol–water system(2023)2 cited